Pulmonary edema treatment

One specific manifestation of mitomycin C is the development of a thrombotic microangiopathy similar to the hemolytic and uremic syndrome. It is associated with noncardiogenic pulmonary edema in 50% of the cases. Mortality is high from 50% to 95% when associated with pulmonary edema. Treatment is supportive with plasmapheresis, steroids, and occasionally dialysis. 

Untoward effects of both E and NE (usually to a lesser degree) are anxiety, headache, cerebral hemorrhage (from vasopressor effects), cardiac arrhythmias, especially in presence of digitaUs and certain anesthetic agents, and pulmonary edema as a result of pulmonary hypertension. The minimum subcutaneous lethal dose of E is about 4 mg, but recoveries have occurred after accidental overdosage with 16 mg subcutaneously and 30 mg intravenously, followed by immediate supportive treatment. 

---